Amylyx Pharmaceuticals Inc
NASDAQ:AMLX

Watchlist Manager
Amylyx Pharmaceuticals Inc Logo
Amylyx Pharmaceuticals Inc
NASDAQ:AMLX
Watchlist
Price: 4.05 USD 2.27% Market Closed
Market Cap: 277.6m USD
Have any thoughts about
Amylyx Pharmaceuticals Inc?
Write Note

Relative Value

The Relative Value of one AMLX stock under the Base Case scenario is 1.42 USD. Compared to the current market price of 4.05 USD, Amylyx Pharmaceuticals Inc is Overvalued by 65%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

AMLX Relative Value
Base Case
1.42 USD
Overvaluation 65%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
72
vs Industry
87
Median 3Y
7.7
Median 5Y
7.7
Industry
2.5
Forward
3.1
vs History
vs Industry
42
Median 3Y
-4.3
Median 5Y
-4.3
Industry
21.8
Forward
-0.9
vs History
vs Industry
39
Median 3Y
-9.8
Median 5Y
-9.8
Industry
16.1
vs History
vs Industry
30
Median 3Y
-9.6
Median 5Y
-9.6
Industry
23.8
vs History
61
vs Industry
76
Median 3Y
3
Median 5Y
3
Industry
2.1
vs History
72
vs Industry
45
Median 3Y
5.8
Median 5Y
5.8
Industry
2.7
Forward
0.5
vs History
50
vs Industry
66
Median 3Y
1
Median 5Y
1
Industry
5.2
vs History
vs Industry
15
Median 3Y
-8.4
Median 5Y
-8.4
Industry
13.5
Forward
-0.1
vs History
vs Industry
18
Median 3Y
-8.3
Median 5Y
-8.3
Industry
16.8
Forward
-0.1
vs History
vs Industry
5
Median 3Y
-9.4
Median 5Y
-9.4
Industry
15.2
vs History
vs Industry
6
Median 3Y
-9.3
Median 5Y
-9.3
Industry
19.3
vs History
50
vs Industry
13
Median 3Y
15.6
Median 5Y
15.6
Industry
1.9

Multiples Across Competitors

AMLX Competitors Multiples
Amylyx Pharmaceuticals Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Amylyx Pharmaceuticals Inc
NASDAQ:AMLX
277.6m USD 1.4 -1.1 -0.4 -0.4
JP
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
776 550.9T JPY 4 211 733 -5 347 888.9 -5 459 134.4 -5 046 864.6
US
Eli Lilly and Co
NYSE:LLY
729.3B USD 17.8 87.1 46.9 52.3
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
DK
Novo Nordisk A/S
CSE:NOVO B
2.6T DKK 9.6 27.5 19.1 21.8
US
Johnson & Johnson
NYSE:JNJ
347.8B USD 4 23.7 11.5 14.9
US
Merck & Co Inc
NYSE:MRK
248.3B USD 3.9 20.4 10.3 12.4
CH
Roche Holding AG
SIX:ROG
197.2B CHF 3.4 17.2 9.7 11.5
UK
AstraZeneca PLC
LSE:AZN
159B GBP 4.1 31 169.2 253.5
CH
Novartis AG
SIX:NOVN
169.7B CHF 3.8 10.8 9.4 13
US
Pfizer Inc
NYSE:PFE
149.4B USD 2.5 35.1 10.5 15.8
P/S Multiple
Revenue Growth P/S to Growth
US
Amylyx Pharmaceuticals Inc
NASDAQ:AMLX
Average P/S: 382 942
1.4
-100%
N/A
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
4 211 733
22%
194 879.4
US
Eli Lilly and Co
NYSE:LLY
17.8
109%
0.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
578.3
29%
19.9
DK
Novo Nordisk A/S
CSE:NOVO B
9.6
77%
0.1
US
Johnson & Johnson
NYSE:JNJ
4
13%
0.3
US
Merck & Co Inc
NYSE:MRK
3.9
20%
0.2
CH
Roche Holding AG
SIX:ROG
3.4
15%
0.2
UK
AstraZeneca PLC
LSE:AZN
4.1
35%
0.1
CH
Novartis AG
SIX:NOVN
3.8
17%
0.2
US
Pfizer Inc
NYSE:PFE
2.5
10%
0.3
P/E Multiple
Earnings Growth P/E to Growth
US
Amylyx Pharmaceuticals Inc
NASDAQ:AMLX
Average P/E: 31.6
Negative Multiple: -1.1
N/A N/A
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 347 888.9 N/A N/A
US
Eli Lilly and Co
NYSE:LLY
87.1
446%
0.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
27.5
86%
0.3
US
Johnson & Johnson
NYSE:JNJ
23.7
-23%
N/A
US
Merck & Co Inc
NYSE:MRK
20.4
7 300%
0
CH
Roche Holding AG
SIX:ROG
17.2
54%
0.3
UK
AstraZeneca PLC
LSE:AZN
31
177%
0.2
CH
Novartis AG
SIX:NOVN
10.8
31%
0.3
US
Pfizer Inc
NYSE:PFE
35.1
719%
0
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
Amylyx Pharmaceuticals Inc
NASDAQ:AMLX
Average EV/EBITDA: 459.2
Negative Multiple: -0.4
N/A N/A
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 459 134.4 N/A N/A
US
Eli Lilly and Co
NYSE:LLY
46.9
195%
0.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
151%
25.5
DK
Novo Nordisk A/S
CSE:NOVO B
19.1
84%
0.2
US
Johnson & Johnson
NYSE:JNJ
11.5
14%
0.8
US
Merck & Co Inc
NYSE:MRK
10.3
331%
0
CH
Roche Holding AG
SIX:ROG
9.7
23%
0.4
UK
AstraZeneca PLC
LSE:AZN
169.2
64%
2.6
CH
Novartis AG
SIX:NOVN
9.4
8%
1.2
US
Pfizer Inc
NYSE:PFE
10.5
31%
0.3
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
Amylyx Pharmaceuticals Inc
NASDAQ:AMLX
Average EV/EBIT: 2 010.8
Negative Multiple: -0.4
N/A N/A
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 046 864.6 N/A N/A
US
Eli Lilly and Co
NYSE:LLY
52.3
211%
0.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
675%
26.2
DK
Novo Nordisk A/S
CSE:NOVO B
21.8
83%
0.3
US
Johnson & Johnson
NYSE:JNJ
14.9
28%
0.5
US
Merck & Co Inc
NYSE:MRK
12.4
675%
0
CH
Roche Holding AG
SIX:ROG
11.5
28%
0.4
UK
AstraZeneca PLC
LSE:AZN
253.5
131%
1.9
CH
Novartis AG
SIX:NOVN
13
58%
0.2
US
Pfizer Inc
NYSE:PFE
15.8
68%
0.2

See Also

Discover More
Back to Top